FDA Warning Letter Asks Bayer To Fix Manufacturing Practices In German Facility
This article was originally published in The Pink Sheet Daily
FDA says Bayer's facility in Bergkamen, Germany, is still not up to par with good manufacturing practices in the U.S.
You may also be interested in...
Delayed appointments of new CEO and CFO may strengthen German pharma's M&A capabilities.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.